Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $5 price target on Aveo Oncology (AVEO), after the company announced a partnership with AstraZeneca (AZN) to conduct a Phase I/II study of durvalumab + tivozanib in in first-line liver cancer. The analyst also noted that, following positive Phase III TIVO-3 data in 3rd+ line RCC for tivozanib, Aveo intends to file an NDA in the first half of 2019 with mature OS data likely in Q3 of 2019. Tenthoff expects FDA approval and launch in 2020 forecasting U.S. sales of $32M in 2020 growing to $218M in 2025.

Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.